|
Objective: To study the effects of telmisartan on essential hypertension with paroxysmal atrial fibrillation. Methods: 68 cases of essential hypertension with paroxysmal atrial fibrillation were randomly divided into treatment group (telmisartan group, 34 patients) and the control group (amlodipine group, 34 patients) . All patients were took orally aspirin enteric-coated tablets of and other conventional anti-platelet drugs for 12 months. Follow-up time was once every 4 weeks. The patient’s heart rate, blood pressure, drug adverse reactions, the frequency and duration of atrial fibrillation recurrence were recorded. Electrocardiogram was done once every three months. The serum high-sensitivity C reactive protein (hs-CRP) level was measured once every six months. Echocardiography was finished by the end of the study. Results: 33 patients in the control group and 31 patients in treatment group have finished the follow-up.There was no signifficant difference in the age, sex, blood pressure, and heart rate of patients before and after treatment between two groups( P> 0.05). The level of serum hs-CRP(mol/L), left atrial diameter(cm), Pmax(ms)and P wave dispersion(ms)of patients , in the control group before treatment, respectively.There was no significant difference between two groups( P> 0.05).Compared with the control group , The level of serum hs-CRP(P <0.001), left atrial diameter(P <0.001), Pmax(P <0.001)and Pd(P <0.001)of patients were significantly reduced after treatment.The rate of atrial fibrillation recurrence were 36.67% and 68.75%, respectively.There were significant difference after treatment between two groups(χ~2 = 6.402, P <0.05). Conclusion: AngiotensinⅡ(AngⅡ) receptor antagonist telmisartan can decrease significantly the blood pressure, left atrial diameter, the Pmax, P wave dispersion, the serum hs- CRP levels and the recurrence rate of the patients of essential hypertention with paroxysmal atrial fibrillation.
|